Investigating the in vivo bioequivalence of Tamsulosin 0.4 mg
Not Applicable
- Conditions
- In the present study, the products will be administered to healthy volunteers..
- Registration Number
- IRCT20220211053992N7
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
General Health (in terms of Liver, Heart and Kidney)
Age (18-59 years old)
Exclusion Criteria
Smoking
Pregnancy
Alcohol and drug addiction
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of drug. Timepoint: In 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 48 hours after drug administration. Method of measurement: HPLC (High performance liquid chromatography).
- Secondary Outcome Measures
Name Time Method